Antibody Effector Function and Virology
Antibody Effector Function and Virology
批准号:
8516873
负责人:
Cynthia Ann Derdeyn
金额:
$54.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-07-01 至 2016-06-30
关键词:
AntibodiesAntibody FormationAntibody SpecificityAntigensAntiviral AgentsAutologousAvidityB-LymphocytesBindingBiologicalBiological AssayCellsCellular biologyControl AnimalCytolysisDNADisease ProgressionFrequenciesGaggingGeneticGenetic VariationGenital systemGoalsGranulocyte-Macrophage Colony-Stimulating FactorHIV-1HumanHumoral ImmunitiesImmuneImmune responseImmunoglobulin AImmunoglobulin GInfectionInfection preventionInstructionMacacaMeasuresMediatingModelingMolecularMolecular CloningMonkeysMonoclonal AntibodiesMucous MembraneNaturePathway interactionsPeripheralPlasmaPlasmablastPropertyRoleSIVSerumSiteSurfaceSystemVaccinatedVaccinationVaccinesVaginaVariantViralViral Envelope ProteinsVirionVirusantibody-dependent cell cytotoxicitybaseneutralizing antibodynovel strategiespre-clinicalpressurerectalresponsetransmission processvirologyvirus envelope
中文摘要
在这项应用项目一中使用的DNA PRIME,MVA Boost模型中,到目前为止发现的唯一与黏膜攻击保护相关的免疫关联是GM-CSF介导的疫苗诱导的抗体与挑战病毒膜结合的亲和力。保护机制尚不清楚,但提示了体液免疫反应的重要作用。因此,病毒学和抗体分析核心的目标是研究(I)基于GM-CSF的抗体保护的机制(项目一),(Ii)促进肠道粘膜内体液免疫的新策略(项目二),以及(Iii)疫苗和攻击诱导的抗体特异性(NHP单抗核心)。病毒学核心是这些研究的核心,将评估中和和Fc介导的抗体活动是否与疫苗诱导的保护相关。我们将专注于粘膜分泌物和血浆中针对病毒蛋白Env和Gag的抗体。中和抗体成分通过与病毒粒子相关形式的Env结合并防止靶细胞感染来介导抗病毒活性。虽然中和抗体可能是疫苗的关键成分,但到目前为止,还没有人诱导出能够介导基因多样性病毒中和的NAB,这一特征对于保护感染HLV-1的人类至关重要。其他非中和抗体活性与预防感染和疾病进展有关。这些包括识别在受感染细胞表面表达的Env,导致该细胞的裂解(ADCC),以及增强其他可能有助于病毒抑制的非裂解机制(ADCVI)。最后,HIV-1和SIV通过生殖器粘膜的传播与遗传瓶颈有关,因此我们将确定在接种疫苗和对照猴子中建立感染的变异的特征,以确定疫苗诱导的抗体是否对环境病毒施加了选择性压力。具体来说,病毒学核心将确定外周和粘膜中的抗体活性是否与疫苗接种后对阴道内攻击的免疫保护相关,并调查是否存在明显的筛选效应。
英文摘要
In the DNA prime, MVA boost model to be used in Project One of this application, the only immune correlate of protection against mucosal challenge identified thus far is the GM-CSF mediated avidity of vaccine-elicited antibody binding to the envelope ofthe challenge virus. The mechanism for protection is unknown but suggests an important role for the humoral immune response. The goals of the Virology and Antibody Assay Core are therefore to investigate (i) a mechanism for GM-CSF-based antibody protection (Project One), (ii) novel strategies for promoting humoral immunity within the gut mucosa (Project Two), and (iii) vaccine and challenge induced antibody specificities (NHP Monoclonal Antibody Core). The Virology Core is central to these studies and will assess whether neutralizing and Fc-mediated antibody activities correlate with vaccine-induced protection. We will focus on antibodies within mucosal secretions and plasma against viral proteins Env and Gag. The neutralizing antibody component mediates antiviral activity by binding to the virion associated form of Env and preventing infection of a target cell. While neutralizing antibodies are likely to be a critical component of a vaccine, to date no one has elicited Nabs that can mediate neutralization of genetically diverse viruses, a feature that is critical for protection of HlV-1 infected humans. Other nonneutralizing antibody activities have been associated with protection against acquisition and disease progression. These involve recognition ofthe Env expressed on the surface of an infected cell, leading to lysis of that cell (ADCC) in addition to augmenting other non-lytic mechanisms that may contribute to viral suppression (ADCVI). Finally, transmission of HIV-1 and SIV across the genital mucosa is associated with a genetic bottleneck, and we will therefore characterize the variants that establish infection in the vaccinated and control monkeys to determine whether vaccine-induced antibodies imposed selective pressure on Env. Specifically, the Virology Core will determine whether peripheral and mucosal IgG and IgA-mediated antibody activities correlate with immune protection against intravaginal challenge following vaccination and investigate whether a sieve effect is evident.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interplay of the HIV-1 Env cytoplasmic tail, Gag-MA, and membrane: resolving molecular detail and blocking assembly
-
批准号:10772333
-
项目类别:
-
资助金额:$82.76万
-
财政年份:2023
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization
-
批准号:10620979
-
项目类别:
-
资助金额:$82.28万
-
财政年份:2023
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Novel treatment for respiratory distress due to SARS-CoV2 infection
-
批准号:10284733
-
项目类别:
-
资助金额:$23.46万
-
财政年份:2021
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Novel treatment for respiratory distress due to SARS-CoV2 infection
-
批准号:10426353
-
项目类别:
-
资助金额:$19.56万
-
财政年份:2021
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Discovery of Novel Epitopes for Antibody Dependent Cell-mediated Cytotoxicity Against HIV-1 Infected Cells
-
批准号:10031027
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2020
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Discovery of Novel Epitopes for Antibody Dependent Cell-mediated Cytotoxicity Against HIV-1 Infected Cells
-
批准号:10113530
-
项目类别:
-
资助金额:$22.31万
-
财政年份:2020
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
NOVEL EPITOPES THAT MEDIATE BROAD NEUTRALIZATION OF CLADE B AND C HIV-1 ISOLATES
-
批准号:8357473
-
项目类别:
-
资助金额:$3.72万
-
财政年份:2011
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Antibody Effector Function and Virology
-
批准号:8326368
-
项目类别:
-
资助金额:$53.37万
-
财政年份:2011
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
ANTIBODY NEUTRALIZATION AND ESCAPE IN SUBTYPE C HIV-1
-
批准号:8357423
-
项目类别:
-
资助金额:$7.43万
-
财政年份:2011
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
NOVEL EPITOPES THAT MEDIATE BROAD NEUTRALIZATION OF CLADE B AND C HIV-1 ISOLATES
-
批准号:8172428
-
项目类别:
-
资助金额:$2.74万
-
财政年份:2010
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
ANTIBODY NEUTRALIZATION AND ESCAPE IN SUBTYPE C HIV-1
-
批准号:8172357
-
项目类别:
-
资助金额:$5.48万
-
财政年份:2010
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
ANTIBODY NEUTRALIZATION AND ESCAPE IN SUBTYPE C HIV-1
-
批准号:7958165
-
项目类别:
-
资助金额:$5.67万
-
财政年份:2009
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
NOVEL EPITOPES THAT MEDIATE BROAD NEUTRALIZATION OF CLADE B AND C HIV-1 ISOLATES
-
批准号:7958254
-
项目类别:
-
资助金额:$2.84万
-
财政年份:2009
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
ROLE OF V1V2 IN HIV TENASMISSION AND PATHOGENESIS
-
批准号:7715739
-
项目类别:
-
资助金额:$6.8万
-
财政年份:2008
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
ROLE OF V1V2 IN HIV TENASMISSION AND PATHOGENESIS
-
批准号:7562594
-
项目类别:
-
资助金额:$6.55万
-
财政年份:2007
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
ROLE OF V1V2 IN HIV TENASMISSION AND PATHOGENESIS
-
批准号:7349255
-
项目类别:
-
资助金额:$5.97万
-
财政年份:2006
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
ROLE OF V1V2 IN HIV TENASMISSION AND PATHOGENESIS
-
批准号:7166012
-
项目类别:
-
资助金额:$5.24万
-
财政年份:2005
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Antibody Neutralization and Escape of Subtype C HIV-1
-
批准号:7769461
-
项目类别:
-
资助金额:$43.56万
-
财政年份:2004
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Determinants of Neutralization Breadth in Early HIV-1 Infection
-
批准号:8541334
-
项目类别:
-
资助金额:$80.23万
-
财政年份:2004
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
Determinants of Neutralization Breadth in Early HIV-1 Infection
-
批准号:8842576
-
项目类别:
-
资助金额:$82.07万
-
财政年份:2004
-
负责人:Cynthia Ann Derdeyn
-
依托单位:
海外基金